TerminatedNot Applicable

Assessment of Donor Derived Cell Free DNA and Utility in Lung Transplantation

Stopped: Due to COVID and staffing shortages we decided to end the study with 40 participants instead of 50.

United States40 participantsStarted 2020-06-29

Plain-language summary

The use of Allosure to identify and quantify circulating donor-derived cell-free DNA to quantitate allograft injury in the early post-transplant period and determine its relationship to allograft failure.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Participant is willing and able to give informed consent for participation in the study. * Male or Female, aged 18 years or above. * Denovo lung transplant recipient * Ability to understand written and spoken English Exclusion Criteria: * Previous transplant or multi-organ transplant * Unable to have blood draw for medical reason

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Number of Participants With Primary Graft Dysfunction/Allograft Rejection 24 Hours Post Transplant

Timeframe: 24 hours post transplant

Number of Participants With Primary Graft Dysfunction/Allograft Rejection 48 Hours Post Transplant

Timeframe: 48 hours post transplant

Number of Participants With Primary Graft Dysfunction/Allograft Rejection 72 Hours Post Transplant

Timeframe: 72 hours post transplant

Number of Participants With Allograft Rejection 3 Months Post Transplant

Timeframe: 3 months post transplant

Number of Participants With Allograft Rejection 6 Months Post Transplant

Timeframe: 6 months post transplant

Number of Participants With Allograft Rejection 9 Months Post Transplant

Timeframe: 9 months post transplant

Number of Participants With Allograft Rejection 12 Months Post Transplant

Trial details

NCT IDNCT04318587

SponsorPablo Sanchez

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-12-31

Results submitted2024-01-02

View on ClinicalTrials.gov More Lung Transplant Failure and Rejection trials